JP2012010713A5 - - Google Patents

Download PDF

Info

Publication number
JP2012010713A5
JP2012010713A5 JP2011220539A JP2011220539A JP2012010713A5 JP 2012010713 A5 JP2012010713 A5 JP 2012010713A5 JP 2011220539 A JP2011220539 A JP 2011220539A JP 2011220539 A JP2011220539 A JP 2011220539A JP 2012010713 A5 JP2012010713 A5 JP 2012010713A5
Authority
JP
Japan
Prior art keywords
amino acid
protein
papillomavirus
acid sequence
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011220539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012010713A (ja
Filing date
Publication date
Priority claimed from DE19944435907 external-priority patent/DE4435907C2/de
Priority claimed from DE1995126752 external-priority patent/DE19526752C2/de
Application filed filed Critical
Publication of JP2012010713A publication Critical patent/JP2012010713A/ja
Publication of JP2012010713A5 publication Critical patent/JP2012010713A5/ja
Withdrawn legal-status Critical Current

Links

JP2011220539A 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 Withdrawn JP2012010713A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19944435907 DE4435907C2 (de) 1994-10-07 1994-10-07 Papillomavirusähnliche Partikel und deren Anwendung
DEP4435907.1 1994-10-07
DE1995126752 DE19526752C2 (de) 1995-07-21 1995-07-21 Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
DE19526752.4 1995-07-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008303257A Division JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013112548A Division JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Publications (2)

Publication Number Publication Date
JP2012010713A JP2012010713A (ja) 2012-01-19
JP2012010713A5 true JP2012010713A5 (enExample) 2012-04-26

Family

ID=25940851

Family Applications (6)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2008303257A Withdrawn JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2008303257A Withdrawn JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Country Status (13)

Country Link
US (6) US6066324A (enExample)
EP (2) EP0809700B1 (enExample)
JP (6) JPH11504801A (enExample)
AT (1) ATE325875T1 (enExample)
AU (2) AU4270196A (enExample)
CA (1) CA2202090C (enExample)
DE (3) DE122007000092I1 (enExample)
DK (1) DK0809700T3 (enExample)
ES (1) ES2264563T3 (enExample)
LU (2) LU91390I2 (enExample)
NL (2) NL300324I1 (enExample)
PT (1) PT809700E (enExample)
WO (1) WO1996011272A2 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE122007000092I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP2000515741A (ja) 1996-07-17 2000-11-28 アメリカ合衆国 感染性パピローマウイルス偽ウイルス粒子
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE341339T1 (de) * 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
CA2295316C (en) * 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AU2003200653B2 (en) * 1997-10-06 2007-01-18 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) * 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19812940A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
EP1105157B1 (en) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20040146531A1 (en) * 1999-09-30 2004-07-29 Active Biotech Ab Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
WO2002004007A2 (en) * 2000-07-06 2002-01-17 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
SI1506222T1 (sl) * 2002-05-17 2009-10-31 Universty Of Cape Town Himerni L1-proteini humanega papilomavirusa 16, ki obsegajo L2-peptid, delci, podobni virusu, pripravljeni iz njih, in postopek za pripravo delcev
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
DK2154149T3 (da) * 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
EP2217699A4 (en) * 2007-10-22 2012-11-28 Univ Rochester RESPIRATORY SYNCYTIAL VIRUS VACCINE BASED ON CHIMERIC PAPILLOMAVIRUS-SIMILAR PARTICLES OR CAPSOMERS
EP2479187A1 (en) * 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Hpv関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力hpv免疫アッセイ
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CN103732250A (zh) * 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
RU2610174C2 (ru) 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
JP6198278B2 (ja) 2011-09-08 2017-09-20 ユニキュアー アイピー ビー.ブイ. Aav調製物からの混入ウイルスの除去
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
CN113508125A (zh) * 2018-12-28 2021-10-15 小利兰·斯坦福大学托管委员会 工程化乙型肝炎核心多肽
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
ES3034186T3 (en) * 2019-07-19 2025-08-13 Sinocelltech Ltd Chimeric papillomavirus l1 protein
CN114127295B (zh) * 2019-07-19 2024-05-14 神州细胞工程有限公司 嵌合的人乳头瘤病毒16型l1蛋白
WO2021013067A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
PL4001298T3 (pl) 2019-07-19 2025-06-16 Sinocelltech Ltd Kompozycja o poliwalentnej immunogenności na wirusa brodawczaka ludzkiego
CN114127097B (zh) * 2019-07-19 2024-09-17 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Hpvワクチン
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
CN117836010A (zh) 2021-06-21 2024-04-05 优尼科生物制药有限公司 改进的裂解程序
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ES2194839T3 (es) * 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
EP1835029A1 (en) 1992-06-25 2007-09-19 Georgetown University Papillomavirus vaccines
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ATE492289T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE122007000092I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Similar Documents

Publication Publication Date Title
JP2012010713A5 (enExample)
RU2006120402A (ru) Оптимизированная экспрессия hpv 58 l1 в дрожжах
RU2006137363A (ru) Оптимизированная экспрессия hpv 52 l1 в дрожжах
RU2006114701A (ru) Оптимизированная экспрессия l1 hpv45 в дрожжах
RU2005132603A (ru) Оптимизированная экспрессия hpv 31 l1 в дрожжах
JP2007507207A5 (enExample)
Lowy et al. Prophylactic human papillomavirus vaccines
RU2014102200A (ru) Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
Xu et al. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes
WO2010118424A3 (en) Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
JP2015037430A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
Tjalma et al. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer
JP2014221052A5 (enExample)
MX376568B (es) Vacunas mejoradas para el virus del papiloma humano y métodos para utilizarlas.
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2013523686A5 (enExample)
JP2015508284A5 (enExample)
JP2019502404A5 (enExample)
WO2024169804A1 (zh) 一种基于Tac启动子的质粒表达载体构建及其用途
Oumeslakht et al. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency
WO2024140160A1 (zh) 人乳头瘤病毒hpv39 l1蛋白的表达和类病毒样颗粒及其制备方法
Webb et al. Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein
JP2013540421A5 (enExample)
JP2002532434A5 (enExample)
JP2008539184A5 (enExample)